Kawasaki disease (KD) is an acute, systemic, febrile vasculitis that occurs during infancy and is the most common cause of childhood coronary artery disease.\(^1\) Although, its etiology has not been definitively determined, recent studies have focused on the increased inflammatory cytokines in KD pathology.\(^2,3\) The clinical features include an existence of fever persisting more than five days with mucocutaneous and lymphatic manifestations that are commonly self-limiting. However, the most serious complication is the coronary artery involvement that can be mortal. With the routine use of intravenous immunoglobulin (IVIG) treatment, the incidence of coronary artery lesions (CALS) has declined from 23% to 8%.\(^5\) On the other hand, some patients are at risk for resistance to IVIG treatment and development of CALs.\(^6\) In Turkey, KD was reported as the second most common type of vasculitis in a nationwide study by Ozen et al.\(^7\), despite the real prevalence being unknown. Previous studies about KD from Turkey reported higher prevalence of coronary arterial involvement than Japanese children based studies.\(^8-12\)

Many studies have previously been conducted about the risk factors of KD, and patients with atypical age presentation, elevated acute phase reactants and liver function tests were reported as high risk.\(^10-12\) The Japanese-based risk scoring systems such as that by Kobayashi, Egami, and Sano was reported as inadequate for fully determining the risks for IVIG resistance and CALs in Western populations living in North America.

### ABSTRACT

Kawasaki disease (KD) is the most common cause of childhood coronary artery disease. The incidence of coronary artery lesions (CALS) has declined with the routine use of intravenous immunoglobulin (IVIG) treatment, but there is still considerable risk for resistance to IVIG treatment and development of CALs. The present study was aimed to determine the risk factors in Turkish children with IVIG resistant KD and coronary artery involvement. Clinical, laboratory and echocardiographic data were retrospectively analyzed in 94 Kawasaki patients. IVIG resistant and responsive groups were compared. The IVIG resistant group had a higher rate of CALs compared to the IVIG responsive group (p<0.05). Duration of fever ≥ 9.5 days, C-reactive protein (CRP) ≥ 88 mg/L and Neutrophil/lymphocyte ratio (NLR) ≥1.69 were the best cutoff values for predicting IVIG resistance before treatment. The criteria for at least two of these three predictors were considered to be statistically significant risk factors for detecting IVIG resistance in KD before treatment (76.47% sensitivity, 71.05% specificity and 95% CI were 50.1-93.19% and 59.51-80.89%, respectively). Based on the clinical and laboratory features, we established a new risk-scoring system for predicting IVIG resistance in a cohort of Turkish children with KD. This may be useful for choosing optimal treatment for KD to prevent coronary artery involvement.

**Key words:** Kawasaki disease, IVIG resistance, risk score.
America, Israel and the UK. We had a similar concern, when we tried to estimate the risk of IVIG resistance using the Japanese risk scoring systems for our patients in Turkey. The sensitivity and specificity were 17.65% and 92.11% for Egami, 40.00% and 89.66% for Kobayashi, and 40.00% and 94.44% for Sano, regarding our patients. Also, a recent paper by Yang et al. had a different scoring system for Chinese children with KD. We also evaluated our patients using the related score, and found the sensitivity and specificity as 43.75% and 80.43%, respectively. These scoring systems have limited predictive capacity for IVIG resistance of KD in Turkish children.

The present study was aimed to determine the risk factors in Turkish children with IVIG resistant KD and coronary artery involvement for early effective treatment.

Material and Methods

This study was approved by Dokuz Eylul University Non-Interventional Research Ethics Committee (2018/21-07, 02.08.2018).

Subjects and Definitions of KD: This retrospective study was performed by reviewing the medical records of 94 Kawasaki patients who had received IVIG treatment in a tertiary center between 1996 and 2018. Patients were diagnosed with following six major clinical signs: i) fever persisting for five or more days (≥38.0 °C); ii) bilateral conjunctival congestion; iii) changes of the lips and oral cavity; iv) polymorphous exanthema; v) changes of peripheral extremities; and vi) acute non-purulent cervical lymphadenopathy. Complete KD (cKD) was diagnosed when subjects had at least five of the six clinical signs, and incomplete KD (iKD) was defined as having four or fewer major signs, with or without cardiac lesions. Laboratory findings including leukocytosis, anemia, elevation of erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), elevated alanine aminotransferase (ALT) levels, and sterile pyuria were considered while diagnosing iKD. According to these definitions, patients were classified as 61 cKD and 33 iKD. Demographic data including age and sex, and clinical information such as the duration of fever before IVIG treatment were noted.

Treatment and Definition of IVIG Resistance

All patients were treated with IVIG (2 gr/kg) and high dose acetyl salicylic acid (80-100 mg/kg/day). The IVIG resistance was defined as persistent fever (≥ 38.0 °C) 48 hours after administration of initial dose of IVIG. Second dose of IVIG was given to IVIG resistant patients, and high dose steroids (IV methyl prednisolone 30 mg/kg dose) were administered in patients who were resistant to recurrent IVIG treatments.

Laboratory Assessment

Hemogram parameters such as white blood cell count (WBC), absolute neutrophil count (Neu), absolute lymphocyte count (Lym), hemoglobin count (Hb), absolute platelet count (Plt), mean platelet volumes (MPV), and acute phase reactants such as CRP and ESR were recorded prior to the IVIG treatment and 48-hours following the treatment. In addition, biochemical parameters such as serum albumin (Alb) and total bilirubin (T-bil), liver function tests (LFT), and electrolyte levels of sodium (Na⁺), potassium (K⁺) and calcium (Ca++) were noted. Neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratios (PLR) were calculated from the available data. The difference between the assessments related to ESR, CRP and WBC values were recorded as delta values (∆WBC, ∆ESR and ∆CRP).

Echocardiographic Assessment and Definition of CALs

Echocardiographic assessment was performed on all patients at the time of diagnosis and in the subacute phase (two weeks after IVIG). Coronary artery involvement was determined in 31 patients (33%) before initial IVIG treatment. Coronary artery lesions were
listed as perivascular echogenicity, ectasia/dilatation and aneurysm, according to severity. Perivascular echogenicity was defined as echogenicity of pericoronary tissue minus blood pool. Coronary artery ectasia and dilatation were defined if the internal diameter was up to 1.5 times that of the adjacent coronary artery, and as presenting a luminal dilatation up to 3 mm in children under the age of 5 years or 4.0 mm in children 5 years of age or older. Coronary artery aneurysms were defined and classified according to the criteria established by the Japanese Ministry of Health and Welfare guidelines as follows: Small aneurysm: localized dilatation showing an inner diameter ≤ 4 mm (in children ≥5 years: the internal diameter of a segment <1.5 times compared to an adjacent segment). Medium aneurysm: aneurysm showing an inner diameter > 4 mm and < 8 mm (in children ≥5 years: the internal diameter of a segment 1.5~4 times compared to an adjacent segment). Giant aneurysm: aneurysm showing an internal diameter ≥ 8 mm (in children ≥5 years: the internal diameter of a segment >4 times compared to an adjacent segment). The CALs were sorted according to this severity classification such that perivascular echogenicity 19.35%, ectasia and dilatation in coronary arteries 61.30% and coronary artery aneurysms 19.35%.

Statistical Analysis
Statistical analysis was performed using SPSS 20 software. Chi-square or Fisher’s exact test (when expected count was below 5 in any of the cells) was used to compare categorical variables. Shapiro-Wilk test was performed to evaluate homogeneity of the values. Homogeneously distributed values were presented as mean±SD and heterogeneously distributed values were presented as median and interquartile ranges (25%-75%). Homogenous values were estimated by one-way ANOVA and independent T-test, while heterogeneous values were tested by nonparametric tests. Variables having statistically significant differences among groups were evaluated by receiver operating characteristic (ROC) curves to determine the optimal cut-off values, and relevant odds ratios (OR) were calculated. p<0.05 was considered as statistically significant.

Results
Of the 94 patients included in the study, 55 (58.5%) were male and 39 (41.5%) were female and the ratio was 1.41. The median age at the time of diagnosis was 35 (19-52)* months. CALs were observed at echocardiographic evaluation in 31 patients (33%). Seventeen patients (18.1%) were IVIG resistant. 61 patients were evaluated as cKD (64.9%) and 33 patients as iKD (35.1%). No statistically significant difference was found between complete and iKD groups in terms of age, gender, laboratory and echocardiographic data (Table I).

Risk Factors and Predictive Tools for IVIG Resistance
The IVIG resistant group had a higher duration of fever before treatment, and a higher rate of CALs compared to the IVIG responsive group (p<0.05). There was no significant difference in the distribution of severity of coronary artery lesions between groups (Table I).

When two groups were compared prior to IVIG, neutrophil/lymphocyte ratio (NLR) and CRP parameters were statistically higher in the IVIG resistant group. Also in the same group, other inflammatory markers such as ESR, and Neu count were found to be higher, and Hb and Lym count values were lower than the IVIG responsive group (p>0.05). In further evaluations two days following initial IVIG administration, NLR values were still found to be statistically higher in the IVIG-resistant group; while the Lym count, Na, K, and Ca values were statistically lower (Table II). There was no significant difference between the two groups in terms of delta values including ∆WBC, ∆ESR and ∆CRP.
The predictive value of the variables before initial IVIG treatment revealed duration of fever (p=0.039), CRP (p=0.017) and NLR (p=0.029) as independent predictors of resistance to treatment for KD. ROC curves applied to each variable revealed cut-off values as: duration of fever≥9.5 days, CRP≥88 mg/L and NLR ≥1.69. The criteria for at least two of the three predictors were considered to be statistically significant risk factors for detecting IVIG resistance in KD before treatment (76.47% sensitivity, 71.05% specificity and 95% confidence intervals were 50.1-93.19% and 59.51-80.89%, respectively). The predictive values and OR of each parameters are shown in Table III, and related ROC-curve is presented in Figure 1.

Risk Factors and Predictive Values of Coronary Arterial Lesions
Regarding demographic-clinical data and echocardiographic findings, increased duration of fever prior to IVIG treatment, and IVIG resistance were found as significant determiners in patients with CALs (p <0.05) (Table IV).

Regarding the laboratory parameters, no statistically significant risk factor for coronary artery involvement was detected prior to IVIG treatment. On the other hand, after first IVIG treatment, lower hemoglobin and higher Plt were determined to increase the risk of CALs (p<0.05) (mean Hb count was 10.2±1.5 gr/dL and median Plt count was 583 (409-706) x10^3/μL in

**Table 1.** Comparison of demographic, clinic and echocardiographic data between IVIG responsive and IVIG resistant groups.

| Parameters                  | IVIG responsive | IVIG resistant | p value |
|-----------------------------|-----------------|----------------|---------|
| Age months                  | 34 (21-54) *    | 36 (12-49) *   | 0.426   |
| Gender male/female          | 1.40            | 1.42           | 0.572   |
| Clinic Type (complete/incomplete) | 1.75        | 2.4           | 0.466   |
| Duration of fever before IVIG days | 7 (6-10) *   | 10 (7-20) *   | 0.039   |
| CALs                        | 21 (45.7%)      | 10 (54.4%)     | 0.009   |
| Perivascular echogenicity   | 4 (5.2%)        | 2 (11.8%)      | 0.208   |
| Coronary ectasia/dilatation | 13 (35.3%)      | 6 (16.9%)      | 0.191   |
| Aneurism                    | 4 (5.2%)        | 2 (11.8%)      | 0.208   |

p<0.05, *median (25%-75%)
IVIG: intravenous immunglobulin, CALs: coronary artery lesions

**Fig. 1.** ROC-curve of the factors for predicting IVIG resistance.

**Fig. 2.** ROC-curve of the factors for predicting CALs.
Table II. Comparison of laboratory values between IVIG responsive and IVIG resistant groups. Evaluation of before and after IVIG values.

| Parameters | Before IVIG | 2 Days After IVIG |
|------------|-------------|-------------------|
|            | IVIG response | IVIG resistant | P value | IVIG response | IVIG resistant | P value |
| Hb g/dL    | n= 77 (81.9%) | n=17 (18.1%) | 0.109 | n= 77 (81.9%) | n=17 (18.1%) | 0.047 |
| WBC 10^3/uL | 14.75 ± 6.15** | 15.08 ± 5.95** | 0.838 | 10.4 (8.0-12.5) * | 11.6 (7.0-15.1) * | 0.671 |
| Plt 10^3/uL | 395 (325-514) * | 352 (284-649) * | 0.551 | 458 (387-641) * | 397 (298-502) * | 0.064 |
| Neu 10^3/uL | 8.2 (4.3-13) * | 9.87 (7-15) * | 0.065 | 4.4 (3.3-7.2) * | 5.65 (3.80-10.20) * | 0.191 |
| Lym 10^3/uL | 3.6 (2.6-5.5) * | 3.0 (1.6-3.82) * | 0.137 | 4.40 (3.40-6.20) * | 3.60 (2.50-4.50) * | 0.045 |
| NLR Neu/Lym | 1.69 (0.74-3.32) * | 3.0 (2.0-7.13) * | 0.029 | 1.07 (0.53-1.78) * | 1.79 (1.27-3.38) * | 0.023 |
| PLR Plt/Lym | 101.76 (80.36-157.04) * | 122.15 (98.89-361.11) * | 0.097 | 104.56 (78.65-153.18) * | 101.32 (80.67-161.36) * | 0.774 |
| MPV fl | 7.3 (6.7-8.0) * | 7.9 (7.9-8.1) * | 0.068 | 7.3 (6.9-7.7) * | 7.7 (7.4-8.3) * | 0.197 |
| CRP mg/L | 54.50 | 108.20 | 0.017 | 13.3 (5.0-25.0) * | 25.5 (4.0-84.3) * | 0.191 |
| ESH mm/h | (23.30-116.55) * | (86.0-158.0) * | 0.155 | 65.89±39.76** | 72 ± 48.16** | 0.239 |
| ALT U/L | 25 (15-44) * | 31 (24-59) * | 0.173 | 26 (17-37) * | 20 (12-121) * | 0.954 |
| AST U/L | 30 (21-43) * | 25 (17-45) * | 0.068 | 33 (19-42) * | 29 (20-59) * | 0.440 |
| T. bil mg/dL | 0.32 (0.20-0.61) * | 0.21 (0.20-1.00) * | 0.946 | 0.30 (0.19-0.41) * | 0.29 (0.20-0.80) * | 0.571 |
| Alb g/dL | 3.8 (3.4-4.1) * | 3.7 (3.1-4.2) * | 0.525 | 3.6 (3.4-3.9) * | 3.5 (3.2-3.6) * | 0.153 |
| Na mmol/L | 137 (135-139) * | 135 (132-137) * | 0.066 | 138.04 ± 3.23** | 135.64 ± 2.09** | 0.012 |
| K mmol/L | 4.47 ± 0.59** | 4.48 ± 0.17** | 0.428 | 4.68 ±0.59** | 4.00 ± 0.64** | 0.001 |
| Ca mg/dL | 9.38 ± 0.07** | 9.16 ± 0.17** | 0.426 | 9.44 ± 0.56** | 8.99 ± 0.58** | 0.023 |

Table III. ROC analyses and odds ratios for best cut-off values of variables for predicting IVIG resistance before treatment.

| Variable          | Value | Sensitivity | Specificity | Discriminative ability | Odds ratio |
|-------------------|-------|-------------|-------------|------------------------|------------|
| Duration of fever before IVIG | 9.5 days | 58.8% | 72.7% | 0.667±0.080 | 3.809 |
| CRP before IVIG  | 88.0 mg/L | 70.0% | 64.7% | 0.669±0.076 | 4.40 |
| NLR before IVIG  | 1.69 | 93.3% | 43.4% | 0.679±0.070 | 4.40 |

p<0.05, *Median (25%-75%), **Mean ± Standard deviation
Hb: hemoglobin, WBC: White blood cell, Plt: platelet count, Neu: absolute neutrophil count, Lym absolute lymphocyte count, NLR: neutrophil/lymphocyte ratio, PLR: platelet/lymphocyte ratio, MPV: mean platelet volume, CRP: C reactive protein, ESH: erythrocyte sedimentation rate, AST: aspartate aminotransferase, ALT: alanine aminotransferase, T. bil: total bilirubin, Alb: albumin, Na: sodium, K: potassium, Ca: calcium.

Table III. ROC analyses and odds ratios for best cut-off values of variables for predicting IVIG resistance before treatment.

| Variable          | Value | Sensitivity | Specificity | Discriminative ability | Odds ratio |
|-------------------|-------|-------------|-------------|------------------------|------------|
| Duration of fever before IVIG | 9.5 days | 58.8% | 72.7% | 0.667±0.080 | 3.809 |
| CRP before IVIG  | 88.0 mg/L | 70.0% | 64.7% | 0.669±0.076 | 4.40 |
| NLR before IVIG  | 1.69 | 93.3% | 43.4% | 0.679±0.070 | 4.40 |

p<0.05, *Median (25%-75%), **Mean ± Standard deviation
Hb: hemoglobin, WBC: White blood cell, Plt: platelet count, Neu: absolute neutrophil count, Lym absolute lymphocyte count, NLR: neutrophil/lymphocyte ratio, PLR: platelet/lymphocyte ratio, MPV: mean platelet volume, CRP: C reactive protein, ESH: erythrocyte sedimentation rate, AST: aspartate aminotransferase, ALT: alanine aminotransferase, T. bil: total bilirubin, Alb: albumin, Na: sodium, K: potassium, Ca: calcium.

CALs (+) group, and 11.2±1.2 gr/dl and 453 (342-511) x10^3/uL in CALs (-) group, respectively.

The predictive value of the variables revealed duration of fever before initial IVIG treatment (p=0.050) and Plt counts two days after IVIG treatment (p=0.014) as independent predictors of coronary artery involvement. ROC curves applied to each variable revealed cut-off values.
as; duration of fever ≥ 9.5 days before IVIG, which had an OR 3.41 (51.6% sensitivity and 71.4% specificity), and Plt count after IVIG ≥ 670x10^3/ul which had an OR 5.5 (35.7% sensitivity and 95.3% specificity) for CALs. ROC-curve of the factors for predicting CALs is presented in Figure 2 for predicting CALs.

Discussion

Recent literature about KD in children reports better morbidity and mortality rates related with decreased incidence of coronary arterial disease. On the other hand, there is still a significant number of patients with IVIG resistance, and 15-25% of them have CALs. In the literature, there are many risk-scoring systems from different countries to predict IVIG resistance and CALs. However, using the same parameters for all countries is inadequate due to differences in genetic and environmental factors. There is no risk-scoring system of KD in Turkish children to the best of our knowledge. In the current study, we designed a risk-scoring system to predict IVIG resistant cases with 76.47% sensitivity, and 71.05% specificity.

Resistance to the initial IVIG treatment is a high-risk factor for CALs. The current study determined the rate for developing CALs as 33%, and there was a positive correlation with IVIG resistance. The rate was similar to other Turkish studies, but more frequent than Japanese studies. Duration of fever before IVIG was found to be significantly higher in IVIG resistant and CALs (+) groups, in this study. This period was ≥ 9.5 days, which had an OR of 3.8 for IVIG resistance (58.8% sensitivity and 72.7% specificity) and 3.4 for CALs (51.6% sensitivity and 71.4% specificity). On the other hand, Egami and Kobayashi’s risk scoring systems reported early administration of IVIG to be a strong predictor for IVIG resistance and coronary artery involvement. They defined fever ≤ 4 days before IVIG as a risk factor. They speculated that, patients who were earlier diagnosed and treated were probably sicker and had greater inflammation. However, Chantashiriwan et al. reported duration of fever ≥ 8 days before IVIG as a predictor of coronary artery aneurism, similar with our results. Also, Gulhan et al. suggested administering initial IVIG treatment within 7 days of illness to prevent cardiac complications. We considered that delayed diagnosis and treatment may cause prolonged inflammation of vessel walls before IVIG treatment, which may create a high risk for IVIG resistance and CALs.

Table IV. Comparison of demographic-clinical data and echocardiographic findings.

| Parameters          | CALs (-) 67.01% (n=63) | CALs (+) 32.9% (n=31) |
|---------------------|-------------------------|------------------------|
|                     | Perivascular echogenicity 19.35% (n=6) | Ectasia/Dilatation 61.30% (n=19) | Aneurism 19.35% (n=6) | p value |
| Age                 | months                  | Perivascular echogenicity 19.35% (n=6) | Ectasia/Dilatation 61.30% (n=19) | Aneurism 19.35% (n=6) | p value |
| Gender              | m/f                     | 36 (27-57)*            | 29 (14-40)* | 33 (16-54)* | 23 (6-42)* | 0.367 |
| Clinic              | (cKD/iKD)               | 1.07                   | 5           | 2.16       | 1          | 0.337 |
| Duration of fever   | days                    | 7 (5-10)*              | 13 (5-25)* | 8 (7-14)* | 21 (10-25)* | 0.050 |
| before IVIG         |                         | a                      | b           | b          | b          |       |
| IVIG resistance     | %                       | 12.5*                  | 33.3*       | 31.6*      | 33.3*      | 0.021 |

p < 0.05, *Median (25%-75%)

IVIG: intravenous immunoglobulin, CALs: coronary artery lesions, iKD: incomplete Kawasaki disease, cKD: complete Kawasaki disease.
In the literature, CRP ≥ 100 mg/L (Kobayashi et al.) and ≥ 70 mg/L (Sano et al.) was defined as a risk factor for IVIG resistance. Regarding IVIG resistant cases which had higher CRP values, we compared the related values with IVIG resistant and IVIG responsive groups in the current study. CRP values ≥ 88 mg/L had an OR 4.4 (70% sensitivity and 64.7% specificity) for IVIG resistance. In a recent study, Yang et al. reported this cut-off value as 90 mg/L, which was similar to our results.

Studies about prognostic factors of many infectious and inflammatory disorders suggested that instead of WBC count, using absolute neutrophil and lymphocyte counts (Neu and Lym) and neutrophil/lymphocyte ratio (NLR) might be more predictive for IVIG resistance in KD. Zahorec et al. reported that higher Neu and NLR with lower Lym were associated with severe inflammatory response. Kawamura et al. reported that NLR value before IVIG ≥3.83 and one day after IVIG ≥1.27 were the best cut-off values for predicting IVIG resistance. Similarly, a study by H-J Cho et al. reported that higher NLR values before initial IVIG treatment were associated with increased risk for IVIG resistance and lower NLR changes before and 2 days after IVIG were a predictive tool for coronary artery abnormalities. In current study, we reported best cut-off values of NLR value for IVIG resistance as NLR ≥1.69 before IVIG which had an OR of 4.40 (93.3% sensitivity and 43.4% specificity) and ≥1.25 two days after IVIG which had an OR of 11.29 (85.7% sensitivity and 65% specificity) for IVIG resistance.

Increased pro-inflammatory cytokines stimulate megakaryocyte proliferation leading to an increase in platelet counts. Plt during the acute phase tend to decrease in patients with severe KD. Egami and Kobayashi speculated that it might be related with intravascular consumption, reflecting greater inflammation. They also stated that Plt ≤300x10³/mm³ was a predictor for IVIG resistance. We found no statistically significant difference in the IVIG resistant group. Patients had lower Plt both before and after IVIG. However, Plt two days after first IVIG was ≥ 670x10³ /uL (OR: 15.5) in CALs (+) group, which was significantly higher than CALs (-) group. This cut-off value had a 35.7% sensitivity and 93.5% specificity.

Hyponatremia has been associated with increased vascular permeability and inappropriate antidiuretic hormone secretion due to increased inflammatory cytokine levels, in the course of KD. Sodium values under 133 mmol/L and 135 mmol/L was defined as a risk factor for Kobayashi and Yang, respectively. In our study, lower sodium levels were detected in the IVIG resistant group, both before and after IVIG treatment, without significance.

This study defined three criteria for IVIG resistance in KD prior to treatment: Duration of fever before IVIG ≥ 9.5 days, CRP ≥ 88 mg/L and NLR value ≥ 1.69. Following initial therapy with IVIG, if NLR value was ≥ 1.25, it also predicted ongoing IVIG resistance, possibly implying a need for steroid therapy instead of IVIG.

In summary, based on the clinical and laboratory features, we established a new risk-scoring system for predicting IVIG resistance in KD. This may be useful for choosing optimal treatment for KD before coronary artery involvement. Our findings should be supported by multicenter studies in Turkey.

Acknowledgement

The authors would like to thank Assoc.Prof. Korcan Demir for his valuable contribution in the statistics of the study.
REFERENCES

1. McCrindle BW, Rowley AH, Newburger JW, et al. American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, treatment, and long-term management of Kawasaki disease: A Scientific Statement for Health Professionals from the American Heart Association. Circulation 2017; 135: e927-e999.

2. Hara T, Nakashima Y, Sakai Y, Nishio H, Motomura Y, Yasasaki S. Kawasaki disease: a matter of innate immunity. Clin Exp Immunol 2016; 186: 134-143.

3. Huang YH, Lo MH, Cai XY, Kuo HC. Epigenetic hypomethylation and upregulation of NLRC4 and NLRP12 in Kawasaki disease. Oncotarget 2018; 9: 18939-18948.

4. Chen KYH, Messina N, Germano S, et al. Innate immune responses following Kawasaki disease and toxic shock syndrome. PLoS One 2018; e0191830.

5. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315: 341-347.

6. Ha KS, Jang GY, Lee J, Lee KC, Son CS. Laboratory markers in incomplete Kawasaki disease according to coronary artery outcome. Korean Circ J 2018; 48: 287-295.

7. Ozen S, Bakkaloglu A, Dusunsel R, et al; Turkish Pediatric Vasculitis Study Group Childhood vasculitides in Turkey: a nationwide survey. Clin Rheumatol 2007; 26: 196-200.

8. Kayiran SM, Dindar A, Gurakan B. An evaluation of children with Kawasaki disease in Istanbul: a retrospective follow-up study. Clinics (Sao Paulo) 2010; 65: 1261-1265.

9. Ozdemir H, Ciftci E, Tapisiz A, et al. Clinical and epidemiological characteristics of children with Kawasaki disease in Turkey. J Trop Pediatr 2010; 56: 260-262.

10. Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006; 149: 237-240.

11. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006; 113: 2606-2612.

12. Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007; 166: 131-137.

13. Sleeper LA, Minich LL, McCrindle BM, et al; Pediatric Heart Network Investigators. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr 2011; 158: 831-835.e3.

14. Davies S, Sutton N, Blackstock S, et al. Predicting IVIG resistance in UK Kawasaki disease. Arch Dis Child 2015; 100: 366-368.

15. Arane K, Mendelsohn K, Mimouni M, et al. Japanese scoring systems to predict resistance to intravenous immunoglobulin in Kawasaki disease were unreliable for Caucasian Israeli children. Acta Paediatr 2018; 107: 2179-2184.

16. Yang S, Song R, Zhang J, Li X, Li C. Predictive tool for intravenous immunoglobulin resistance of Kawasaki disease in Beijing. Arch Dis Child 2019; 104: 262-267.

17. Ayusawa M, Sonobe T, Uemura S, et al; Kawasaki Disease Research Committee. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int 2005; 47: 232-234.

18. Sudo D, Monobe Y, Yashiro M, et al. Coronary artery lesions of incomplete Kawasaki disease: a nationwide survey in Japan. Eur J Pediatr 2012; 171: 651-656.

19. Wang Y, Wang W, Gong F, et al. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease. Arthritis Rheum 2013; 65: 805-814.

20. Kurotobi S, Nagai T, Kawakami N, Sano T. Coronary diameter in normal infants, children and patients with Kawasaki disease. Pediatr Int 2002; 44: 1-6.

21. Kibata T, Suzuki Y, Hasegawa S, et al. Coronary artery lesions and the increasing incidence of Kawasaki disease resistant to initial immunoglobulin. Int J Cardiol 2016; 214: 209-215.

22. Xie T, Wang Y, Fu S, et al. Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease. Pediatri Rheumatol Online J 2017; 15: 17.

23. Gülhan B, Kesici S, Beken S, et al. Varying clinical features of Turkish Kawasaki disease patients. Turk J Pediatr 2012; 54: 1-6.
24. Chantasirirawan N, Silvilairat S, Makonkawkeyoon K, Pongprot Y, Sittiwangkul R. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease. Paediatr Int Child Health 2018; 38: 209-212.

25. Soliman WM, Sherif NM, Ghanima IM, El-Badawy MA. Neutrophil to lymphocyte and platelet to lymphocyte ratios in systemic lupus erythematosus: relation with disease activity and lupus nephritis. Reumatol Clin 2018. doi: 10.1016/j.reuma.2018.07.008.

26. Yoon NB, Son C, Um SJ. Role of the neutrophil-lymphocyte count ratio in the differential diagnosis between pulmonary tuberculosis and bacterial community-acquired pneumonia. Ann Lab Med 2013; 33: 105-110.

27. Zahorec R. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001; 102: 5-14.

28. Kawamura Y, Takeshita S, Kanai T, Yoshida Y, Nonoyama S. The combined usefulness of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in predicting intravenous immunoglobulin resistance with Kawasaki disease. J Pediatr 2016; 178: 281-284.e1.

29. Cho HJ, Bak SY, Kim SY, et al. High neutrophil:lymphocyte ratio is associated with refractory Kawasaki disease. Pediatr Int 2017; 59: 669-674.

30. Klinger M, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 2002; 22: 913-922.

31. Lim GW, Lee M, Kim HS, Hong YM, Sohn S. Hyponatremia and syndrome of inappropriate antidiuretic hormone secretion in Kawasaki disease. Korean Circ J 2010; 40: 507-513.